share_log

Jin Medical International Ltd. Announces Exercise of the Underwriters' Over-Allotment Option

Jin Medical International Ltd. Announces Exercise of the Underwriters' Over-Allotment Option

Jin Medical International Ltd.宣布行使承销商的超额配股权
GlobeNewswire ·  2023/04/06 22:40

Changzhou City, China, April 06, 2023 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (the "Company" or "JinMed") (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced that Prime Number Capital, LLC, as the representative of the underwriters of the Company's initial public offering ("IPO"), has partially exercised the over-allotment option to purchase an additional 47,355 ordinary shares at the IPO price of $8.00 per share. As a result, the Company has raised gross proceeds of $378,840, in addition to the previously announced IPO gross proceeds of $8,000,000, before deducting underwriting discounts and offering expenses.

中国常州市,2023年4月6日(GLOBE NEWSWIRE)——开曼群岛控股公司Jin Medical International Ltd(“公司” 或 “JinMed”)(纳斯达克股票代码:ZJYL)今天宣布,作为公司首次公开募股(“IPO”)承销商代表的Prime Number Capital, LLC已部分行使超额行使以每股8.00美元的IPO价格额外购买47,355股普通股的配股权。因此,在扣除承保折扣和发行费用之前,除了先前宣布的8,000,000,000美元的首次公开募股总收益外,公司还筹集了378,840美元的总收益。

Prime Number Capital, LLC acted as the sole bookrunner for the IPO. SBI China Capital Financial Services Limited acted as the co-manager for the IPO. Hunter Taubman Fischer & Li LLC acted as counsel to the Company, and Kaufman & Canoles, P.C. acted as counsel to the underwriters.

Prime Number Capital, LLC是首次公开募股的唯一账簿管理人。SBI中国资本金融服务有限公司担任首次公开募股的联席经理。Hunter Taubman Fischer & Li LLC担任该公司的法律顾问,Kaufman & Canoles, P.C. 担任承销商的法律顾问。

A registration statement on Form F-1 (File No. 333-259767) relating to the IPO, as amended, has been filed with the Securities and Exchange Commission (the "SEC") and was declared effective by the SEC on March 27, 2023. The IPO was being made only by means of a prospectus. Copies of the final prospectus related to the IPO may be obtained from Prime Number Capital, LLC by email at info@pncps.com. In addition, a copy of the final prospectus can also be obtained via the SEC's website at www.sec.gov.

经修订的与首次公开募股有关的F-1表格(文件编号333-259767)的注册声明已提交给美国证券交易委员会(“SEC”),并由美国证券交易委员会于2023年3月27日宣布生效。首次公开募股仅通过招股说明书进行。与首次公开募股有关的最终招股说明书的副本可通过电子邮件从Prime Number Capital, LLC获得,电子邮件地址为 info@pncps.com。此外,最终招股说明书的副本也可以通过美国证券交易委员会的网站www.sec.gov获得。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约或招揽购买本文所述证券的要约,在根据任何此类州或司法管辖区的证券法进行注册或资格认证之前,此类要约、招标或出售是非法的州或司法管辖区也不得出售这些证券。

About Jin Medical International Ltd.

关于 金医疗国际有限公司

Founded in 2006 and headquartered at Changzhou City, Jiangsu Province of China, the Company, through its Chinese operating entities, designs and manufactures wheelchairs and living aids products for people with disabilities, the elderly, and people recovering from injuries. The Company's Chinese operating entities operate 2 manufacturing plants with approximately 228,257 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. The Company's Chinese operating entities have established relationships with over 40 distributors in China, and over 20 in the other regions of the world where it currently sells the products. The majority of its wheelchair products, with more than 30 models, are sold to dealers in Japan and China, including Nissin Medical Industries Co., Ltd, one of the largest medical device distributors in Japan. The Company's Chinese operating entities own 106 patents and are in the process of registering 22 additional patents with the Patent Administration Department of the People's Republic of China and continuously deliver innovative wheelchair designs that are both lightweight and ergonomic each year. For more information, please visit: .

该公司成立于 2006 年,总部位于中国江苏省常州市,通过其中国运营实体为残疾人、老年人和受伤康复者设计和制造轮椅和生活辅助产品。该公司的中国运营实体在中国江苏省常州市和泰州市经营两座制造工厂,总面积约为228,257平方英尺。该公司的中国运营实体已与中国的40多家分销商建立了关系,并在其目前销售产品的世界其他地区的20多家分销商建立了关系。其大多数轮椅产品有30多种型号,销往日本和中国的经销商,包括日本最大的医疗器械分销商之一日信医疗工业株式会社。该公司的中国运营实体拥有106项专利,并且正在向中华人民共和国专利管理部另外注册22项专利,并且每年持续提供既轻巧又符合人体工程学的创新轮椅设计。欲了解更多信息,请访问: 。

Forward-Looking Statement

前瞻性陈述

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the expected trading of its Ordinary Shares on the Nasdaq Capital Market and the closing of the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

本新闻稿包含前瞻性陈述。前瞻性陈述包括有关计划、目标、目标、战略、未来事件或绩效的陈述,以及除历史事实陈述以外的基本假设和其他陈述。当公司使用 “可能、“将”、“打算”、“应该”、“相信”、“期望”、“预期”、“项目”、“估计” 等词语或与历史问题无关的类似表达方式时,它是在发表前瞻性陈述。 这些前瞻性陈述包括但不限于 公司关于以下内容的声明 预期的 交易 它的 普通股 纳斯达克资本市场发行结束。前瞻性陈述不能保证未来的业绩,涉及风险和不确定性,可能导致实际业绩与前瞻性陈述中讨论的公司预期存在重大差异。这些陈述受不确定性和风险的影响,包括但不限于 与市场状况和按预期条件完成首次公开募股有关的不确定性,以及向公司提交的注册声明的 “风险因素” 部分中讨论的其他因素 。出于这些原因,除其他外,提醒投资者不要过分依赖本新闻稿中的任何前瞻性陈述。公司向美国证券交易委员会提交的文件中讨论了其他因素,这些文件可在以下网址进行审查 www.sec.gov。公司没有义务公开修改这些前瞻性陈述,以反映本陈述发布之日之后发生的事件或情况。

For more information, please contact:

欲了解更多信息,请联系:

Underwriters

承销商s

Prime Number Capital LLC

素数资本有限责任公司

Ms. Xiaoyan Jiang, Chairwoman

董事长姜晓燕女士

Email:xj@pncps.com

电子邮件:xj@pncps.com

Phone: 516-582-9666

电话:516-582-9666

Investor Relations

投资者关系

Wealth Financial Services LLC

财富金融服务有限责任公司

Janice Wang

王珍妮

Email: services@wealthfsllc.com

电子邮件: services@wealthfsllc.com

Phone: +86 13811768599

电话:+86 13811768599

+1 628 283 9214

+1 628 283 9214


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发